GA-SYNCRON
Syncron, the largest privately-owned global leader in intelligent SaaS solutions dedicated to End-to-End Continuous Service LifeCycle Management, announced today that it has been named a Leader in the IDC MarketScape: Worldwide B2B Price Optimization and Management Applications 2021 Vendor Assessment (doc # US46742021, September 2021). Syncron is providing a complimentary excerpt of the IDC MarketScape report here .
The IDC MarketScape vendor assessment model is an important competitive evaluation and scoring of the SaaS-based business-to-business price optimization and management solution suppliers available in the global market. According to the IDC MarketScape the nine vendors covered in the IDC MarketScape represent the front-runners and the vendors most representative of any given B2B PO&M application buyer's selection short list. IDC’s research methodology uses a rigorous scoring methodology based on both qualitative and quantitative criteria that results in a single graphical illustration of each vendor’s position within a given market. IDC MarketScape provides a clear, customer influenced framework, in which the product and service offerings, capabilities, and strategies, and current and future market success factors can be meaningfully compared.
The IDC MarketScape report’s profile stated, “After a thorough evaluation of Syncron's offerings and capabilities, IDC has positioned the company in the Leaders category within this 2021 IDC MarketScape for B2B price optimization and management applications.” The report also states that “Syncron has greatly expanded its vision to be the end-to-end service management provider. This is an integrated suite of solutions to optimize inventory, price, and uptime for aftermarket parts and service for B2B or retail-focused companies. This enables Syncron to optimize both price and cost.”
The research positioned Syncron as a leader based on the flexible capabilities and intuitive functionality of Syncron Price, and the company’s deep understanding of the aftermarket industry globally.
The report states that companies should consider Syncron when they’re in the aftermarket service industry and need an end-to-end service management solution with integrated pricing. The IDC MarketScape vendor assessment also recognized three of Syncron’s strengths:
Deep understanding of aftermarket service management: Syncron Price benefits from Syncron Inventory and the company's deep institutional knowledge of the cost side of the equation to manage profit when pricing inventory that is deployed around the world, including location (delivery time, taxes, tariffs), age, and scarcity/replacement value. Customers highly appreciated this experience to set up personalized pricing for specialty parts and kits.
Ease of Use: Customers highly rated Syncron for how easy the product was to learn and use. They liked that it had initiative workflows that were "one to two clicks away from done."
Pricing Agility: Syncron makes it easy to segment and manage huge numbers of parts. Customers liked the ML-driven segmentation workflow that made segmentation easy to implement and gave the user the best choices of which segment the product should be placed in. One customer was managing 300,000 parts with one person while being able to reprice each on a far more regular basis with greater profit.
“Syncron combines its deep knowledge of the global aftermarket industries, with robust solution capabilities, and expert services to substantively increase the efficiency and profitability of an OEM's aftermarket businesses,” says Mark Thomason, Research Director, IDC. “Syncron Price enables manufacturers, dealers, and suppliers to automate and optimize dynamic pricing capabilities, quickly and globally. By leveraging artificial intelligence and machine learning, Syncron Price can segment highly complex product lists and identify otherwise unseen revenue uplift and margin opportunities.”
“At Syncron, we’re committed to empower the world’s leading manufacturers and distributors to drive profitable business and competitive advantage by providing intelligent and connected service experience solutions. We are deeply honored the IDC MarketScape named Syncron a Leader for the Price Optimization and Management category. This acknowledgement follows similar IDC MarketScape recognitions of Syncron and its newly acquired company, Mize, in the areas of Field Service Management (FSM)1 , Service Parts Management (SPM), and Warranty Contract Management (WCM)2 ,” said Dr. Friedrich Neumeyer, CEO of Syncron. “Being recognized as a leader in multiple strategic categories by the IDC MarketScape is validation that our significant innovation investments in AI and ML innovation, user experience, architectural extensibility, scalability, security, and platform are quickly paying dividends. It also echoes Syncron’s nonstop passion and commitment and ability to execute our customers’ success.”
To learn more about Syncron Price, www.syncron.com/price .
About Syncron
Syncron accelerates leading manufacturers and distributors to capitalize on the world's new service economy. We improve aftermarket business profitability, optimize working capital, increase customer loyalty, and enable our customer’s ability to transition successfully to future service-driven business models. With our industry-leading investments in AI and ML, Syncron offers the first, innovative, customer-endorsed, and complete end-to-end intelligent Service Lifecycle Management solution portfolio. Syncron’s offer encompasses leadership solutions such as: service parts inventory, price, equipment uptime, warranty, service contract, and field service management. Delivered on Syncron’s Connected Service Experience (CSX) platform, our solutions offer our customers competitive differentiation through exceptional aftermarket service experiences, while simultaneously driving significant revenue and profit improvements into a manufacturer or distributor’s business. It is no secret that world's top brands trust Syncron, making it the largest privately-owned global leader in intelligent SLM SaaS solutions. For more information, visit syncron.com .
1 IDC MarketScape: Worldwide Manufacturing Field Service Management Applications 2019–2020 Vendor Assessment, Aly Pinder, IDC #US44408719, November 2019
2 IDC MarketScape: Worldwide Manufacturing Warranty and Service Contract Management Applications 2019–2020 Vendor Assessment, Aly Pinder, IDC# US44408619 December 2019
View source version on businesswire.com: https://www.businesswire.com/news/home/20210927005247/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom